Cytarabine: all 556 studies that test it
Page 5 of 6. Open to participants first (82), then studies with results posted, then the rest; newest registration first within each.
- Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01246622Phase 1
- Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALLCompletedNCT01228331Phase 2/3
- Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age Greater Than or Equal to 60 YearsTerminatedNCT01193400Phase 2
- Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid LeukemiaCompletedNCT01132586Phase 1
- Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT01130506Phase 1
- Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01127009Phase 1
- Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic LeukemiaCompletedNCT01085617
- ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML)WithdrawnNCT01067274Phase 3
- A Pharmacokinetic and Efficacy Study of Amonafide L-malate (AS1413) in Combination With Cytarabine in Patients With Acute Myeloid Leukemia (AML)Status unknownNCT01066494Phase 2
- BuEAM Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat Diffuse Large B Cell Lymphoma (DLCBL)Status unknownNCT01063439Phase 2
- Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid LeukemiaCompletedNCT01031368Phase 1
- IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML)TerminatedNCT01027923Phase 1
- Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose CytarabineCompletedNCT00995332Phase 1/2
- Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell LymphomaCompletedNCT00992134Phase 2
- Liposomal Cytarabine for Central Nervous System (CNS)-Treatment in High-risk Acute Lymphoblastic Leukemia (ALL)SuspendedNCT00991744Phase 3
- PROCEDYTE: Depocyte® Administration (Liposomal Cytarabine) as Prophylaxis of Neuromeningeal Infiltration in Acute Lymphoblastic LeukemiaTerminatedNCT00944008Phase 3
- Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic LeukemiaCompletedNCT00940524Phase 1
- Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin LymphomaTerminatedNCT00920153Phase 3
- Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin LymphomaStatus unknownNCT00908180Phase 2
- Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic MalignanciesCompletedNCT00908167Phase 1
- Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic TrioxideCompletedNCT00850304Phase 2
- Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00840684Phase 1/2
- Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk MyelodysplasiaStatus unknownNCT00838240Phase 1/2
- Intrathecal DepoCyte and Lineage-targeted Minimal Residual Disease-oriented Therapy of Acute Lymphoblastic LeukemiaCompletedNCT00795756Phase 2/3
- Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTICStatus unknownNCT00779714Phase 3
- Autologous Stem Cell Transplant for Neurologic Autoimmune DiseasesActive, not recruitingNCT00716066Phase 2
- Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE StudyStatus unknownNCT00715637Phase 3
- Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic LeukemiaCompletedNCT00613457Phase 3
- A Randomized Trial Assessing the Roles of AraC in Newly Diagnosed APL Promyelocytic Leukemia (APL)CompletedNCT00591526Phase 3
- Pilot Trial of Arsenic + Cytarabine in Patients With MyelofibrosisCompletedNCT00572065Early Phase 1
- Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid LeukemiaStatus unknownNCT00544999Phase 1
- Natural Killer Cells in Older Patients With Acute Myeloid LeukemiaCompletedNCT00540956Not applicable
- Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AMLStatus unknownNCT00529880Phase 2
- Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT00516828Phase 1/2
- DepoCyt Plus Temozolomide in Patients With Neoplastic MeningitisTerminatedNCT00515788Phase 1
- A Remission Induction Therapy and Risk-oriented Postremission Strategy for Adult Acute Myelogenous Leukemia (AML)CompletedNCT00495287Phase 3
- Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00488709Phase 4
- 2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)CompletedNCT00483067Phase 2
- A Phase II Study of Ara-C (Cytarabine) in Men With Androgen Independent Prostate CancerCompletedNCT00480090Phase 2
- Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute LeukemiaCompletedNCT00470197Phase 1
- Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic SyndromesCompletedNCT00451997Phase 2
- Low-Dose Cytarabine in Treating Infants With Down Syndrome and Transient Myeloproliferative DisorderWithdrawnNCT00411281Phase 3
- Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)CompletedNCT00408278Phase 4
- Depocyte in the Treatment of CNS Relapse in Patients With Lymphoblastic Leucemia or Very Aggressive LymphomaCompletedNCT00388531Phase 2
- Safety and Efficacy Study of Salvage Chemotherapy (R-ESHAP) to Treat Relapsed and Refractory Aggressive Non-Hodgkin's LymphomaTerminatedNCT00367497Phase 2
- Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative DisordersCompletedNCT00357305Phase 1
- VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid LeukemiaStatus unknownNCT00354276Phase 2
- Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's LymphomaWithdrawnNCT00310128Phase 2
- PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CMLCompletedNCT00303290Phase 1
- Cytarabine and Clofarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaCompletedNCT00295841Phase 1
- Amonafide in Combination With Cytarabine in Secondary AMLCompletedNCT00273884Phase 2
- Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid LeukemiaCompletedNCT00268229Phase 1
- Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00258271Phase 1
- Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's LymphomaCompletedNCT00244946Phase 1
- Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous PatientsTerminatedNCT00219765Phase 1/2
- Phase II Trial of Combined Modality Treatment in Primary Central Nervous System LymphomaCompletedNCT00210314Phase 2
- Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCLStatus unknownNCT00209222Phase 3
- Treatment of Acute Lymphoblastic Leukemia or Aggressive Lymphoma With Relapse in Central Nervous System With DepocytCompletedNCT00199108Phase 2/3
- Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in AdultsCompletedNCT00199082Phase 4
- German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)CompletedNCT00198991Phase 4
- German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaCompletedNCT00198978Phase 4
- Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AMLCompletedNCT00195104Phase 1/2
- Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDSCompletedNCT00195000Phase 2
- Idarubicin Based Combined Modality Therapy in Primary CNS LymphomaCompletedNCT00193973Phase 2
- Treatment of Burkitt Lymphoma/Leukemia and B Large Cell NHLCompletedNCT00187161Phase 2
- Treatment for Patients With Stage III or IV Non-Hodgkin LymphomaCompletedNCT00187122Not applicable
- Large Cell Lymphoma Pilot Study IIICompletedNCT00187070Not applicable
- Study for Treatment of Cancer in Children With Ataxia-telangiectasiaCompletedNCT00187057Not applicable
- Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic LeukemiaTerminatedNCT00187005Phase 3
- Intensified Post Remission Therapy Containing PEG-AsparaginaseCompletedNCT00184041Phase 2
- Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM)CompletedNCT00143975Phase 2
- High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML)CompletedNCT00136448Phase 2
- Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL)Status unknownNCT00131053Phase 2
- Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT00129168Phase 1/2
- Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedNCT00121303Phase 3
- Pravastatin, Idarubicin, and Cytarabine in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00107523Phase 1
- Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT00101153Phase 1
- Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic SyndromesCompletedNCT00098423Phase 1
- PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00093600Phase 1
- Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00093483Phase 1
- Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid LeukemiaCompletedNCT00081822Phase 1
- Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's LymphomaCompletedNCT00080886Phase 2
- Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)CompletedNCT00079482Phase 2
- 3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic MalignanciesCompletedNCT00077181Phase 1
- Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic SyndromeCompletedNCT00077116Phase 2
- Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AMLCompletedNCT00074737Phase 2
- Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS LymphomaCompletedNCT00074191Phase 2
- Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS LymphomaCompletedNCT00074178Phase 2
- GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid LeukemiaCompletedNCT00070551Phase 1
- VNP40101M and Cytarabine in Treating Patients With Hematologic MalignanciesCompletedNCT00070538Phase 1
- Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First RelapseStatus unknownNCT00069966Phase 2
- S0301 Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaCompletedNCT00066794Phase 2
- Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic SyndromeCompletedNCT00065143Phase 2
- 3-AP and Cytarabine in Treating Patients With Hematologic CancerCompletedNCT00064090Phase 1
- Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00058292Phase 1
- Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell TransplantationCompletedNCT00057005Phase 1
- Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00055874Phase 3
- Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous LeukemiaCompletedNCT00053144Phase 1
- Combination Chemotherapy Followed By Filgrastim or Sargramostim in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaCompletedNCT00053131Phase 2
- Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's LymphomaStatus unknownNCT00053105Phase 1